Repros Therapeutics (RPRX +5.7%) will submit a design for a Phase II trial of an oral version of...

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX +5.7%) will submit a design for a Phase II trial of an oral version of its tumor drug Proellex in the next few days as the company attempts to persuade the FDA to lift a suspension on testing of the treatment. The FDA put a study of Proellex on hold in 2009 due to liver toxicity issues.